AS EARLY AS
DAY 3
RAPID
IMPROVEMENT1

(Patient-reported outcome. Post hoc analysis. Results are
descriptive. Definitive conclusions cannot be made.)1,2,a,b

  • SINUS-52: significant improvement was observed as
    early as Week 43
Week 52
SUSTAINED IMPROVEMENT THROUGH WEEK 523
  • -1.10 (95% CI: -1.31, -0.89) LSM difference for DUPIXENT + INCS
    (n=150) vs placebo + INCS (n=153)3,b

Analysis was not multiplicity controlled. Results are descriptive.4

aLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.12, -0.02).1,5

bWeek 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.98 (95% CI: -1.15, -0.81) (-1.21 from a baseline score of 2.77 vs -0.23 from a baseline score of 2.72, respectively) (P<0.0001).4

Loss of Smell (LoS) score (range 0-3); reduced score indicates improvement.3

Improvement in % of patients with UPSIT score >18 through Week 524,c

Analysis was not multiplicity controlled. Results are descriptive. Definitive conclusions cannot be
made.
4

UPSIT score classification:
anosmia (complete loss of
smell) (≤18), severe microsmia
(19-25), moderate microsmia
(26-30),
mild microsmia
(31-34), normosmia (normal
smell appreciation) (35-40).4

c Week 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295,
pooled arms) and placebo + INCS (n=153): 10.52 (95% CI: 8.98, 12.07) (9.71 from a baseline score of 13.53 vs -0.81
from a baseline score of 13.78, respectively) (P<.0001).4

University of Pennsylvania Smell Identification Test (UPSIT) score (range 0-40): higher score indicates improvement.4

INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

Back to efficacy and safety overview
See nasal congestion score